CompanyFATENasdaqSan Diego, CA

Fate Therapeutics

Fate Therapeutics develops off-the-shelf cell therapies using engineered human induced pluripotent stem cells (iPSCs).

SEC EDGAR ClinicalTrials.gov fatetherapeutics.com

8-KSep 28Latest SEC filing

Sep 28Latest story

September 2026

Fate Therapeutics gets $15 million CIRM grant for lupus nephritis CAR T trial

Sep 28Clinical readoutFate Therapeutics FT819

Fate Therapeutics registers Phase 1/2 trial of FT839 across five autoimmune diseases

Sep 2Trial updateFate Therapeutics FT839

August 2026

Fate Therapeutics doses first lupus nephritis patient in Phase 2 FT819 trial, clears FT839 IND

Aug 13Quarterly updateFate Therapeutics FT819